Clinical Trials

BreastClassical hematologyGynecologicThoracic

220 enrolled

Pathologic Complete Response, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Thrombocytopenia, Endometrial Neoplasms

NCT01042379 2026-05-06

I-SPY

Phase 1 Not yet recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06743555 2026-04-28

SAVED LUNG

14 enrolled

Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT07538206 2026-04-20

Vebectotamab Vedotin Combined With Pucotelimab in the Treatment of Locally Advanced Laryngeal Carcinoma

Phase 1/2 Not yet recruiting

10 enrolled

Phase 3 Not yet recruiting

Pathologic Complete Response, Head and Neck Neoplasms

NCT07472868 2026-03-16

MEND-IT II

394 enrolled

Pathologic Complete Response

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

35 enrolled

Phase EARLY_PHASE1 Active not recruiting

Pathologic Complete Response, Rectal Neoplasms

NCT03832569 2026-03-05

Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

17 enrolled

Pathologic Complete Response

NCT06130995 2026-03-05

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Phase 1 Recruiting

46 enrolled

Pathologic Complete Response, Neoplasm, Residual

NCT04055220 2026-02-17

REGOSTA

Phase 2 Not yet recruiting

168 enrolled

Sarcoma

Pathologic Complete Response, Bone Neoplasms, Chondrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Patient Compliance, Sarcoma, Ewing, Osteosarcoma, Histiocytoma, Malignant Fibrous

NCT07397442 2026-02-11

Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer

19 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT07353723 2026-01-20

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

10 enrolled

Pathologic Complete Response, Head and Neck Neoplasms

NCT07328841 2026-01-09

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

Phase 3 Recruiting

456 enrolled

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT07328854 2026-01-09

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

Phase 3 Recruiting

346 enrolled

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT01794572 2025-12-12

TOMMY

Phase NA Terminated

13 enrolled 10 charts

Plasma cell

Pathologic Complete Response, Multiple Myeloma, Recurrence

NCT07007052 2025-11-26

TAGVEN

33 enrolled

Myeloid

Pathologic Complete Response, Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT07066189 2025-10-29

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC

160 enrolled

Phase 3 Active not recruiting

Pathologic Complete Response, Motor Activity, Triple Negative Breast Neoplasms

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

325 enrolled

Phase NA Not yet recruiting

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07164872 2025-09-10

Neoadjuvant Chemotherapy Combined With Preoperative Radiotherapy for Locally Advanced Breast Cancer

50 enrolled

Phase NA Active not recruiting

Pathologic Complete Response, Breast Neoplasms

NCT06087718 2025-08-14

Feasibility of the Maastro Applicator in Rectal Cancer

10 enrolled

Pathologic Complete Response, Radiation Injuries, Rectal Neoplasms

NCT06728982 2025-08-01

Impact Of Metformin In Rectal Cancer Patients

Phase 2/3 Completed

85 enrolled

Pathologic Complete Response

NCT06811844 2025-07-01

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

208 enrolled

Pathologic Complete Response, Nasopharyngeal Neoplasms

NCT05416164 2025-03-26

DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy

595 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT05976815 2025-03-26

KEYMOVE

86 enrolled

LymphoidOther hematologic neoplasm

Pathologic Complete Response, Breast Neoplasms, Motor Activity

NCT04314219 2025-03-13

PTCy-PMAT

Phase 3 Recruiting

264 enrolled

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05350722 2024-12-30

ABLATIVE-2

100 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT05000697 2024-11-27

CCHOWW

216 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT04435197 2024-07-03

PALACE-2

143 enrolled

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response

NCT01340430 2024-05-09

Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer

43 enrolled

Pathologic Complete Response

NCT05659056 2024-04-16

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

65 enrolled

Phase 2 Active not recruiting

Pathologic Complete Response, Breast Neoplasms

NCT01686334 2024-03-12

WIDEA

130 enrolled

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT05103293 2023-12-27

PTC Guiding Neoadjuvant Treatment in Breast Cancer

Other hematologic neoplasm

86 enrolled

BreastOther neoplasm

Pathologic Complete Response, Breast Neoplasms, Pathological Conditions, Signs and Symptoms

NCT06180863 2023-12-26

Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

Phase 2 Withdrawn

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT03125343 2023-11-07

WoW

400 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT05684874 2023-10-30

SarQuantIRM

Phase NA Unknown

25 enrolled

Sarcoma

Pathologic Complete Response, Neoplasms, Sarcoma

NCT05371860 2023-09-22

Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response

Phase 2 Withdrawn

Pathologic Complete Response, Breast Neoplasms

NCT05763992 2023-05-18

BREAKFAST-2

145 enrolled

Pathologic Complete Response, Breast Neoplasms, Fasting, Triple Negative Breast Neoplasms

NCT05750693 2023-03-02

PIK3CA in HER2+ BC and pCR Trial

Phase NA Unknown

58 enrolled

Pathologic Complete Response, Hereditary Sensory and Autonomic Neuropathies

NCT04743102 2023-02-21

BIOPSY

260 enrolled

Pathologic Complete Response, Neoplasm Metastasis, Rectal Neoplasms

NCT02233374 2022-10-28

PRISM

Phase NA Completed

27 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT01648894 2022-07-25

GRECCAR6

Phase 3 Completed

265 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT04293796 2022-06-15

VAB

60 enrolled

Pathologic Complete Response

NCT04781725 2021-11-17

INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer

90 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT01392183 2021-09-20

Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

Classical hematologyOther hematologic neoplasm

69 enrolled 15 charts

Genitourinary

Pathologic Complete Response, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT02907827 2020-12-17

DW-MRi

Phase NA Unknown

100 enrolled

Dermatologic

Pathologic Complete Response, Melanoma

NCT01656252 2020-11-03

PrE0901

Phase 1/2 Terminated

15 enrolled 5 charts

Jacobs syndrome, Pathologic Complete Response, Leukemia, Thrombocytopenia, Leukemia, Myeloid, Acute

NCT03417427 2020-04-27

A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML

Other hematologic neoplasm

100 enrolled

Pathologic Complete Response, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT04225858 2020-01-13

ASICS

Phase NA Not yet recruiting

340 enrolled

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04006041 2019-12-26

Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer

44 enrolled

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response

NCT01216644 2019-06-19

5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

Phase 2/3 Completed

716 enrolled